Payment overview · 2025
General Payments
$2,545.86
16 reported records · 9 companies
Healthcare provider profile · identity verified
George William Kariampuzha, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · TYLER, TX · NPI 1235103201
Verified facts
What the public records show
CMS Open Payments records show George William Kariampuzha, MD received $2,545.86 in general payments during 2025 across 16 reported records.
LivaNova USA, Inc. accounted for 71.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nurtec Odt.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Ubrelvy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PANZYGA as an associated drug or biological on 8346 records involving 3334 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Panzyga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $1,809.44 | 71.1% | 8 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $118.59 | 4.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $113.59 | 4.5% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $110.72 | 4.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $109.66 | 4.3% | 1 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $90.88 | 3.6% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $89.99 | 3.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $85.27 | 3.4% | 1 | 2025 |
| Haemonetics Corporation | Unresolved — no canonical attribution shown | $17.72 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,355.56 | 12 |
| Travel and Lodging | $1,190.30 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VNS Therapy Normalized: vns therapy |
Device | LivaNova USA, Inc. | $1,809.44 | 8 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $118.59 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $113.59 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $110.72 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $109.66 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $89.99 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $85.27 | 1 | 2025 |
Source payment records
|
|||||
| TEG6S HEMOSTASIS SYSTEM Normalized: teg6s hemostasis system |
Device | Haemonetics Corporation | $17.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 77 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
41 | 25 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
172 | 40 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
81 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
77 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PANZYGA open payments reported associated product |
CMS Open Payments — General Payments 8346 supporting records · 3334 recipient NPIs · example record 1228795271 |
Panzyga · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Memantine Hcl | Memantine Hcl | 662 | 133 |
| Gabapentin | Gabapentin | 627 | 133 |
| Topiramate | Topiramate | 550 | 100 |
| Levetiracetam | Levetiracetam | 523 | 102 |
| Pregabalin | Pregabalin | 297 | 62 |
| Lacosamide | Lacosamide | 264 | 55 |
| Clopidogrel | Clopidogrel Bisulfate | 232 | 52 |
| Clonazepam | Clonazepam | 231 | 39 |
| Zonisamide | Zonisamide | 226 | 49 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 188 | 47 |
| Donepezil Hcl | Donepezil Hcl | 185 | 35 |
| Divalproex Sodium | Divalproex Sodium | 178 | 31 |
| Lamotrigine | Lamotrigine | 172 | 22 |
| Qulipta | Atogepant | 172 | 40 |
| Trazodone Hcl | Trazodone Hcl | 168 | 36 |
| Prednisone | Prednisone | 158 | 48 |
| Duloxetine Hcl | Duloxetine Hcl | 157 | 37 |
| Doxepin Hcl | Doxepin Hcl | 151 | 29 |
| Emgality Pen | Galcanezumab-Gnlm | 149 | 27 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 146 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 142 | 27 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 132 | 28 |
| Rizatriptan | Rizatriptan Benzoate | 126 | 36 |
| Primidone | Primidone | 122 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 120 | 28 |
| Oxcarbazepine | Oxcarbazepine | 115 | 20 |
| Propranolol Hcl | Propranolol Hcl | 115 | 27 |
| Sumatriptan Succinate | Sumatriptan Succinate | 112 | 31 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 110 | 27 |
| Sertraline Hcl | Sertraline Hcl | 85 | 19 |
| Rivastigmine | Rivastigmine Tartrate | 84 | 19 |
| Ubrelvy | Ubrogepant | 81 | 21 |
| Nurtec Odt | Rimegepant Sulfate | 77 | 22 |
| Aimovig Autoinjector | Erenumab-Aooe | 75 | 17 |
| Methocarbamol | Methocarbamol | 74 | 21 |
| Nortriptyline Hcl | Nortriptyline Hcl | 74 | 14 |
| Acetazolamide | Acetazolamide | 73 | 14 |
| Alprazolam | Alprazolam | 72 | suppressed |
| Baclofen | Baclofen | 72 | 16 |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 71 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | suppressed |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 66 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 62 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 61 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | suppressed |
| Carbamazepine | Carbamazepine | 60 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 57 | suppressed |
| Amantadine | Amantadine Hcl | 49 | 11 |
| Phenobarbital | Phenobarbital | 48 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 47 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 44 | suppressed |
| Lorazepam | Lorazepam | 43 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 42 | 11 |
| Botox | Onabotulinumtoxina | 41 | 25 |
| Diazepam | Diazepam | 39 | 18 |
| Modafinil | Modafinil | 36 | suppressed |
| Levetiracetam Er | Levetiracetam | 35 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 34 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 33 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 32 | suppressed |
| Methylprednisolone Sodium Succ | Methylprednisolone Sod Succ | 32 | suppressed |
| Lidocaine | Lidocaine | 30 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | suppressed |
| Eszopiclone | Eszopiclone | 29 | suppressed |
| Carbamazepine Er | Carbamazepine | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Tegretol Xr | Carbamazepine | 27 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Panzyga | Immun Glob G(Igg)-Ifas/Glycine | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Rivastigmine | Rivastigmine | 21 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Celecoxib | Celecoxib | 20 | 12 |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 18 | suppressed |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Topiramate Er | Topiramate | 18 | suppressed |
| Clobazam | Clobazam | 17 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Tecfidera | Dimethyl Fumarate | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Betaseron | Interferon Beta-1b | 14 | suppressed |
| Lamotrigine Er | Lamotrigine | 14 | suppressed |
| Rytary | Carbidopa/Levodopa | 14 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Tetrabenazine | Tetrabenazine | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Xcopri | Cenobamate | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 12 | suppressed |
| Neurontin | Gabapentin | 12 | suppressed |
| Omeprazole | Omeprazole | 12 | suppressed |
| Soliris | Eculizumab | 12 | suppressed |
| Tegretol | Carbamazepine | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 11 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,545.86 · 16 records | LivaNova USA, Inc. | AUSTEDO XR, Fintepla, KISUNLA, Leqembi, NURTEC ODT, TEG6S HEMOSTASIS SYSTEM, VNS Therapy, VYALEV | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nurtec Odt play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error